[
  {
    "ts": null,
    "headline": "Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum",
    "summary": "Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]",
    "url": "https://finnhub.io/api/news?id=c855bc73775497dcfd375cfa5707c6a6c5e1909310402e21462db2dc50ab9a0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769870160,
      "headline": "Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum",
      "id": 138315838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]",
      "url": "https://finnhub.io/api/news?id=c855bc73775497dcfd375cfa5707c6a6c5e1909310402e21462db2dc50ab9a0f"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration",
    "summary": "On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...",
    "url": "https://finnhub.io/api/news?id=09b00ab85d96679243219bb793ee68d767631664f3e48c32256bb9fac2c12424",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769843131,
      "headline": "How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration",
      "id": 138313535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...",
      "url": "https://finnhub.io/api/news?id=09b00ab85d96679243219bb793ee68d767631664f3e48c32256bb9fac2c12424"
    }
  }
]